EMA's Modeling & Simulation Group Gears Up For Bigger Role With New Status
Executive Summary
Modeling and simulation approaches are expected to play even a greater role in regulatory decision-making by the European Medicines Agency in the coming years.
You may also be interested in...
EFPIA Picks Holes In EMA's Pediatric Extrapolation Proposals
Pharmaceutical companies are worried about new requirements the European Medicines Agency has proposed on using extrapolation to support the development of pediatric medicines.
EMA Keeps Hold Of Extrapolation Template So Pharma Doesn't Lose Pediatric Focus
The European Medicines Agency is sharing an “extrapolation template” with drug makers on a case-by-case basis to support complex cases of pediatric development. Despite positive feedback, the EMA is holding back from publishing the template on the grounds that companies could get bogged down in technical details and fail to address the right scientific questions.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.